Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility

Monique Vogel, Xinyue Chang, Gilles Sousa Augusto, Mona O. Mohsen, View ORCID ProfileDaniel E. Speiser, Martin F. Bachmann
doi: https://doi.org/10.1101/2021.03.04.433887
Monique Vogel
1Department of Immunology, University clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland
2Department of BioMedical Research, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinyue Chang
1Department of Immunology, University clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland
2Department of BioMedical Research, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles Sousa Augusto
2Department of BioMedical Research, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona O. Mohsen
1Department of Immunology, University clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland
2Department of BioMedical Research, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel E. Speiser
1Department of Immunology, University clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel E. Speiser
  • For correspondence: martin.bachmann@dbmr.unibe.ch daniel.speiser@dbmr.unibe.ch
Martin F. Bachmann
1Department of Immunology, University clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland
2Department of BioMedical Research, University of Bern, Bern, Switzerland
3Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: martin.bachmann@dbmr.unibe.ch daniel.speiser@dbmr.unibe.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Background Several new variants of SARS-CoV-2 have emerged since fall 2020 which have multiple mutations in the receptor binding domain (RBD) of the spike protein.

Objective We aimed to assess how mutations in the SARS-CoV-2 RBD affect receptor affinity to angiotensin-converting enzyme 2 (ACE2) and neutralization by anti-RBD serum antibodies.

Methods We produced a SARS-CoV-2 RBD mutant (RBDmut) with key mutations (E484K, K417N, N501Y) from the newly emerged Brazilian variant. Using Biolayer Interferometry, we analyzed the binding of this mutant to ACE2, and the susceptibility to neutralization by sera from vaccinated mice and COVID-19 convalescent patients.

Results Kinetic profiles showed increased RBDmut - ACE2 affinity compared to RBDwt, and binding of vaccine-elicited or convalescent sera was significantly reduced. Likewise, both sera types showed significantly reduced ability to block RBDmut - ACE2 binding indicating that antibodies induced by RBDwt have reduced capability to neutralize mutant virus.

Conclusion Our physiochemical data show enhanced infectivity and reduced neutralization by polyclonal antibodies of the Brazilian variant of SARS-CoV-2.

Capsule summary SARS-CoV-2 variant with Brazilian RBD mutations shows increased ACE2 affinity and reduced susceptibility to blockage by vaccine-elicited and convalescent sera.

Competing Interest Statement

M. F. Bachmann is a board member of HypoPet AG and of Saiba. All other authors declare no conflict of interest.

Footnotes

  • Funding The work was supported by Saiba AG and the Swiss National Science Foundation (SNF grants 31003A 149925 and 310030-179459) and the International Immunology Centre, Anhui Agricultural University, Hefei, China.

  • Conflict of interests M. F. Bachmann is a board member of HypoPet AG and of Saiba. All other authors declare no conflict of interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 04, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
Monique Vogel, Xinyue Chang, Gilles Sousa Augusto, Mona O. Mohsen, Daniel E. Speiser, Martin F. Bachmann
bioRxiv 2021.03.04.433887; doi: https://doi.org/10.1101/2021.03.04.433887
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
Monique Vogel, Xinyue Chang, Gilles Sousa Augusto, Mona O. Mohsen, Daniel E. Speiser, Martin F. Bachmann
bioRxiv 2021.03.04.433887; doi: https://doi.org/10.1101/2021.03.04.433887

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4079)
  • Biochemistry (8750)
  • Bioengineering (6467)
  • Bioinformatics (23314)
  • Biophysics (11719)
  • Cancer Biology (9135)
  • Cell Biology (13227)
  • Clinical Trials (138)
  • Developmental Biology (7404)
  • Ecology (11360)
  • Epidemiology (2066)
  • Evolutionary Biology (15078)
  • Genetics (10390)
  • Genomics (14001)
  • Immunology (9109)
  • Microbiology (22025)
  • Molecular Biology (8773)
  • Neuroscience (47317)
  • Paleontology (350)
  • Pathology (1419)
  • Pharmacology and Toxicology (2480)
  • Physiology (3701)
  • Plant Biology (8044)
  • Scientific Communication and Education (1427)
  • Synthetic Biology (2206)
  • Systems Biology (6009)
  • Zoology (1247)